Envoy Medical (COCH) Cash from Financing Activities (2021 - 2026)

Envoy Medical has reported Cash from Financing Activities for 6 years, with the latest figure at $27.6 million in Q1 2026.

• Quarterly Cash from Financing Activities rose 675.86% year-over-year to $27.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $40.7 million (up 134.64% YoY) and the FY2025 annual result came in at $16.6 million, down 17.65% from the prior year.
• Cash from Financing Activities advanced to $27.6 million in Q1 2026 per COCH's latest filing, from $6.0 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $27.6 million in Q1 2026 and troughed at -$1.5 million in Q4 2023.
• A 5-year average of $5.5 million and a median of $4.0 million in 2023 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2022 and 2023: Cash from Financing Activities jumped 76633.33% in 2022, then sank 172.7% in 2023.
• Over 5 years, Cash from Financing Activities stood at $2.0 million in 2022, then sank by 172.7% to -$1.5 million in 2023, then surged by 486.31% to $5.6 million in 2024, then climbed by 7.53% to $6.0 million in 2025, then soared by 356.52% to $27.6 million in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $27.6 million, $6.0 million, and $2.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.